<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Mol. Med</journal-id><journal-id journal-id-type="publisher-id">IJMM</journal-id><journal-title-group><journal-title>International Journal of Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1107-3756</issn><issn pub-type="epub">1791-244X</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29207009</article-id><article-id pub-id-type="pmc">5752180</article-id><article-id pub-id-type="doi">10.3892/ijmm.2017.3260</article-id><article-id pub-id-type="publisher-id">ijmm-41-02-0809</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>TAT-fused IP3R-derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca<sup>2+</sup> release</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="af1-ijmm-41-02-0809">1</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Ye</given-names></name><xref ref-type="aff" rid="af2-ijmm-41-02-0809">2</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Weinan</given-names></name><xref ref-type="aff" rid="af3-ijmm-41-02-0809">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="af1-ijmm-41-02-0809">1</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="af1-ijmm-41-02-0809">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yanan</given-names></name><xref ref-type="aff" rid="af1-ijmm-41-02-0809">1</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Yuting</given-names></name><xref ref-type="aff" rid="af2-ijmm-41-02-0809">2</xref></contrib><contrib contrib-type="author"><name><surname>Dou</surname><given-names>Minghan</given-names></name><xref ref-type="aff" rid="af2-ijmm-41-02-0809">2</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Kebang</given-names></name><xref ref-type="aff" rid="af4-ijmm-41-02-0809">4</xref><xref ref-type="corresp" rid="c1-ijmm-41-02-0809"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Liankun</given-names></name><xref ref-type="aff" rid="af1-ijmm-41-02-0809">1</xref><xref ref-type="corresp" rid="c2-ijmm-41-02-0809"/></contrib></contrib-group><aff id="af1-ijmm-41-02-0809">
<label>1</label>Department of Pathophysiology, Basic College of Medicine, Jilin University, Changchun, Jilin 130021</aff><aff id="af2-ijmm-41-02-0809">
<label>2</label>Department of Histology and Embryology, Basic College of Medicine, Jilin Medical University, Jilin, Jilin 132013</aff><aff id="af3-ijmm-41-02-0809">
<label>3</label>Department of Clinical Medicine, College of Clinical Medicine, Jilin University, Changchun, Jilin 130021</aff><aff id="af4-ijmm-41-02-0809">
<label>4</label>Department of Urology, First Hospital of Jilin University, Changchun, Jilin 130031, P.R. China</aff><author-notes><corresp id="c1-ijmm-41-02-0809">Correspondence to: Dr Kebang Hu, Department of Urology, First Hospital of Jilin University, 3302 Jilin Street, Changchun, Jilin 130031, P.R. China, E-mail: <email>hukebang@126.com</email></corresp><corresp id="c2-ijmm-41-02-0809">Professor Liankun Sun, Department of Pathophysiology, Basic College of Medicine, Jilin University, 126 Xinmin Street, Changchun, Jilin 130021, P.R. China, E-mail: <email>sunlk@jlu.edu.cn</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>11</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>41</volume><issue>2</issue><fpage>809</fpage><lpage>817</lpage><history><date date-type="received"><day>12</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Xie et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. In this study, we observed the cytoplasmic and mitochondrial levels of Ca<sup>2+</sup> by confocal laser microscopy. We also detected cell apoptosis using western blot analysis and flow cytometry. The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDP<sup>S</sup>), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca<sup>2+</sup> flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. In addition, TAT-IDP<sup>S</sup> increased cisplatin-induced expression of mitochondrial apoptosis-associated proteins and ER stress-associated proteins. These results indicated that TAT-IDP<sup>S</sup> may enhance the cytotoxicity of cisplatin toward ovarian carcinoma cells by increasing ER Ca<sup>2+</sup> release.</p></abstract><kwd-group><kwd>cisplatin</kwd><kwd>ovarian cancer</kwd><kwd>calcium</kwd><kwd>endoplasmic reticulum</kwd><kwd>peptide</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ovarian cancer is the most common form of gynecological cancer and is a serious threat to women's health and survival worldwide. Cis-diammine-dichloroplatinum (II), also known as cisplatin, is a classic chemotherapy drug that is widely used for the treatment of advanced cancers, including ovarian cancer (<xref rid="b1-ijmm-41-02-0809" ref-type="bibr">1</xref>,<xref rid="b2-ijmm-41-02-0809" ref-type="bibr">2</xref>). Cisplatin exhibits a satisfactory therapeutic effect during the early stages of administration; however, patients often become resistant to cisplatin during long-term administration. It has previously been reported that overexpression of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein facilitates the pathophysiology and cisplatin resistance of cancer by inhibiting apoptosis (<xref rid="b3-ijmm-41-02-0809" ref-type="bibr">3</xref>). Bcl-2 contains BH1, BH2, BH3 and BH4 domains. Bcl-2 has been reported to bind to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist killer via its BH3 domain and inhibit cytochrome <italic>c</italic> release from the mitochondria, thus maintaining mitochondrial integrity. Notably, BH3-mimetic Bcl-2 inhibitors have attracted much attention and have been extensively studied (<xref rid="b4-ijmm-41-02-0809" ref-type="bibr">4</xref>). The BH3-mimetics ABT737 and ABT-263 have been reported to enhance cisplatin sensitivity in cholangiocarcinoma and ovarian carcinoma cells (<xref rid="b5-ijmm-41-02-0809" ref-type="bibr">5</xref>,<xref rid="b6-ijmm-41-02-0809" ref-type="bibr">6</xref>). However, the function of the Bcl-2 BH4 domain in ovarian carcinoma cells remains unclear.</p><p>Bcl-2 has been reported to induce a reduction in endoplasmic reticulum (ER) Ca<sup>2+</sup> load and release via its BH4 domain (<xref rid="b7-ijmm-41-02-0809" ref-type="bibr">7</xref>). The ER is the main store of intracellular Ca<sup>2+</sup> and a crucial organelle in eukaryotic cells. A large release of Ca<sup>2+</sup> from the ER can activate calpain-1, which is a Ca<sup>2+</sup>-dependent cysteine protease responsible for the transition from caspase-4 to cleaved caspase-4, which in turn activates ER stress-induced apoptosis (<xref rid="b8-ijmm-41-02-0809" ref-type="bibr">8</xref>). Furthermore, Ca<sup>2+</sup> release from the ER can enhance mitochondrial Ca<sup>2+</sup> uptake, which is accompanied by a release of cytochrome <italic>c</italic> and activation of the mitochondrial apoptotic pathway (<xref rid="b9-ijmm-41-02-0809" ref-type="bibr">9</xref>). In our previous study, it was demonstrated that the expression of Bcl-2 was higher in cisplatin-resistant SKOV3/DDP ovarian cancer cells compared with in cisplatin-sensitive SKOV3 ovarian cancer cells (<xref rid="b10-ijmm-41-02-0809" ref-type="bibr">10</xref>). A low dose of cisplatin induced apoptosis, which was accompanied by cytoplasmic and mitochondrial Ca<sup>2+</sup> overload in SKOV3 cells, but not in SKOV3/DDP cells (<xref rid="b11-ijmm-41-02-0809" ref-type="bibr">11</xref>). These results suggested that Bcl-2 contributes to cisplatin resistance in ovarian cancer by inhibiting ER Ca<sup>2+</sup> release.</p><p>Bcl-2 inhibits ER Ca<sup>2+</sup> release by directly binding and inhibiting the inositol 1,4,5-trisphosphate receptor (IP3R), which is the main ER Ca<sup>2+</sup> release channel, via its BH4 domain. IP3R transmits signals between the cytoplasm and ER microenvironment, and can modulate the mitochondrial Ca<sup>2+</sup> signal (<xref rid="b12-ijmm-41-02-0809" ref-type="bibr">12</xref>). By deleting the BH4 domain, Liu <italic>et al</italic> demonstrated that the BH4 domain was important for the prosurvival activity of Bcl-2 (<xref rid="b13-ijmm-41-02-0809" ref-type="bibr">13</xref>). Stabilized TAT-fused IP3R-derived peptide (TAT-IDP<sup>S</sup>) can specifically target the BH4 domain of Bcl-2 and reverse Bcl-2-mediated inhibition of IP3-induced Ca<sup>2+</sup> elevation, ultimately increasing Ca<sup>2+</sup>-dependent cell apoptosis (<xref rid="b14-ijmm-41-02-0809" ref-type="bibr">14</xref>). TAT-IDP<sup>S</sup> has been reported to induce apoptosis of diffuse large B-cell lymphoma cells by promoting IP3-induced proapoptotic Ca<sup>2+</sup> signaling (<xref rid="b14-ijmm-41-02-0809" ref-type="bibr">14</xref>). These results indicated that targeting the BH4 domain may induce conversion of Bcl-2 from a prosurvival protein into a proapoptotic protein. Notably, Zhong <italic>et al</italic> indicated that TAT-IDP<sup>S</sup> sensitivity is positively correlated with Bcl-2 expression (<xref rid="b15-ijmm-41-02-0809" ref-type="bibr">15</xref>). Therefore, it may be hypothesized that TAT-IDP<sup>S</sup> increases the sensitivity of cells to cisplatin via IP3-dependent Ca<sup>2+</sup> release in SKOV3/DDP cells.</p><p>The present study aimed to evaluate the effects of TAT-IDP<sup>S</sup> on the cytotoxicity of cisplatin in SKOV3/DDP cells. The results demonstrated that TAT-IDP<sup>S</sup> increased cisplatin-induced apoptosis by increasing Ca<sup>2+</sup> release from the ER to the cytoplasm and mitochondria. These experimental results indicated that TAT-IDP<sup>S</sup>, combined with chemotherapy, may be considered a viable treatment strategy for the prevention and treatment of ovarian cancer.</p></sec><sec sec-type="methods"><title>Materials and methods</title><sec><title>Antibodies and drugs</title><p>Anti-caspase-3 (sc-7272), anti-caspase-4 (sc-56056) and anti-cleaved caspase-4 (sc-22173-R) antibodies (Abs) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-cleaved caspase-3 (ab2302), anti-protein disulfide isomerase (PDI; ab2792) and anti-CCAAT-enhancer-binding protein homologous protein (CHOP; ab11419) Abs were purchased from Abcam (Hong Kong) Ltd. (Hong Kong, China). Anti-&#x003b2;-actin (60008&#x02013;1-Ig), anti-Bcl-2-associated X protein (Bax; 50599-2-Ig), anti-Bcl-2 (12789-1-AP), anti-cytochrome <italic>c</italic> (10993-1-AP), peroxidase-conjugated AffiniPure goat anti-mouse immunoglobulin (Ig)G (H+L) (SA00001-1) and peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H+L) (SA00001-2) Abs were purchased from Proteintech Group, Inc. (Chicago, IL, USA). The anti-calpain-1 catalytic subunit (#31038-1) Ab was purchased from Signalway Antibody LLC (College Park, MD, USA). Cisplatin was purchased from Sigma-Aldrich; Merck KgaA (Darmstadt, Germany) and was dissolved in normal saline for <italic>in vitro</italic> use. TAT-IDP<sup>S</sup> was synthesized and purified by ChinaPeptides Co., Ltd. (Shanghai, China) and was dissolved in ddH<sub>2</sub>O. The sequence for TAT-IDP<sup>S</sup> is RKKRRQRRRGGNVYTEIKCNSLLPLDDIVRV. 2-Aminoethyl diphenylborinate (2-APB; ab120124) was purchased from Abcam (Hong Kong) Ltd.</p></sec><sec><title>Cell lines</title><p>Cisplatin-resistant ovarian cancer SKOV3/DDP cells were obtained from the Chinese Academy of Medical Sciences (Beijing, China) and Peking Union Medical College (Beijing, China). Cells were cultured at 37&#x000b0;C in an atmosphere containing 5% CO<sub>2</sub> in RPMI-1640 culture medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). Cisplatin-resistant SKOV3/DDP cells were maintained in medium containing 1 <italic>&#x003bc;</italic>g/ml cisplatin (Sigma-Aldrich; Merck KGaA) for 24 h to maintain resistance.</p></sec><sec><title>Cell viability assays</title><p>Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. SKOV3/DDP cells were seeded into 96-well culture plates in 100 <italic>&#x003bc;</italic>l medium at a density of 1&#x000d7;10<sup>4</sup> cells/well. After 2 days, agents [cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/ or TAT-IDPS (25 <italic>&#x003bc;</italic>M) in the presence or absence of 50 <italic>&#x003bc;</italic>M 2-APB] were added to quadruplicate wells and incubated for 24 or 48 h at 37&#x000b0;C. For the MTT assay (Beyotime Institute of Biotechnology, Shanghai, China), 20 <italic>&#x003bc;</italic>l/well MTT (5 mg/ml in PBS) was added to each well; after 4 h at 37&#x000b0;C, dimethyl sulfoxide (150 <italic>&#x003bc;</italic>l/well; Beijing Chemical Industry Group Co., Beijing, China) was added and the plates were agitated at room temperature for 10 min. Absorbance was measured at a wavelength of 570 nm using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).</p></sec><sec><title>Western blotting</title><p>Whole-cell protein extracts were isolated from SKOV3/DDP cells using cell lysis buffer [50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM sodium-EDTA, 1 mM EDTA; 1% (v/v) Triton X-100; 2.5 mM sodium pyrophos-phate; 1 mM &#x003b2;-glycerophosphate; 1 mM Na<sub>3</sub>VO<sub>4</sub>; 1 mM NaF; 1 <italic>&#x003bc;</italic>g/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride] for western blotting. Protein concentration was quantified using the Quick Start Bradford protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For western blot analysis, lysates (30 <italic>&#x003bc;</italic>g) were separated by 10% (w/v) SDS-PAGE and were transferred onto immobilon-P transfer membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% (w/v) non-fat dry milk in buffer [10 mM Tris-HCl (pH 7.6), 100 mM NaCl, and 0.1% Tween-20] for 1 h at room temperature and were then incubated with the desired primary Abs [caspase-3 (dilution, 1:200); caspase-4 (dilution, 1:200); cleaved caspase-4 (dilution, 1:200); cleaved caspase-3 (dilution, 1:1,000); PDI (dilution, 1:1,000); CHOP (dilution, 1:1,000); &#x003b2;-actin (dilution, 1:2,000); Bax (dilution, 1:1,000); cytochrome <italic>c</italic> (dilution, 1:1,000); calpain-1 (dilution, 1:200)] overnight at 4&#x000b0;C, followed by incubation with horseradish peroxidase-conjugated secondary Abs (dilution, 1:2,000) for 1.5 h at room temperature. Immunodetection was performed using enhanced chemiluminescence reagents (PE0010-b; Solarbio, New York, NY, USA) and images were captured using Syngene Bio Imaging (Syngene, Cambridge, UK). Protein expression levels were normalized to those of &#x003b2;-actin and the ratios of normalized protein to &#x003b2;-actin are presented as the mean &#x000b1; standard deviation from three independent experiments. Protein expression levels were semi-quantified by densitometry using Quantity One software (version 4.6.9; Bio-Rad Laboratories, Inc.).</p></sec><sec><title>Immunofluorescence staining and confocal laser microscopy</title><p>Cells (4&#x000d7;10<sup>4</sup> cells/well) were cultured on coverslips overnight, following treatment with increasing doses of cisplatin (5, 10 and 15 <italic>&#x003bc;</italic>g/ml) for 24 h at 37&#x000b0;C, and were fixed with 4% (w/v) paraformaldehyde and stained with nuclear Hoechst 33342 (1 <italic>&#x003bc;</italic>g/ml; Sigma-Aldrich; Merck KGaA) for 5 min. Subsequently, the cells were washed with PBS and were examined under an Olympus FV1000 confocal laser microscope (Olympus Corporation, Tokyo, Japan) to reveal cell chromatin condensation. The expression of calpain-1 was examined by indirect immunofluorescence. Cells (4&#x000d7;10<sup>4</sup> cells/ well) were cultured on coverslips overnight, and were then treated with the indicated dose of cisplatin with or without TAT-IDP<sup>S</sup> for 24 h at 37&#x000b0;C, after which the cells were rinsed with PBS three times. Subsequently, cells were fixed with 4% (w/v) paraformaldehyde for 20 min, permeabilized with 0.1% (v/v) Triton X-100 for 5 min, blocked with bovine serum albumin (PA129262; Thermo Fisher Scientific, Inc.), and incubated with anti-calpain-1 (dilution, 1:100) overnight at 4&#x000b0;C. Cells were then incubated with Alexa Fluor 488 donkey anti-rabbit IgG (#R37602, 1:400 dilution; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at room temperature, stained with Hoechst 33342 (1 <italic>&#x003bc;</italic>g/ml) for 5 min at room temperature, and washed with PBS three times. After mounting, cells were examined under an Olympus FV1000 confocal laser microscope (Olympus Corporation). The same parameters of illumination and detection were maintained digitally throughout the experiments.</p></sec><sec><title>Calcium concentration analysis</title><p>The Ca<sup>2+</sup>-sensitive fluorescent dyes Fluo-4/AM (Molecular Probes; Thermo Fisher Scientific, Inc.) and Rhod-2/AM (AAT Bioquest, Sunnyvale, CA, USA) were used to measure Ca<sup>2+</sup> concentration according to the manufacturers' protocols. Prior to exposure to various experimental conditions, the cells were incubated with Fluo-4/AM or Rhod-2/AM for 30 min at 37&#x000b0;C. Cell samples were then analyzed by confocal laser microscopy. All experiments were performed in triplicate.</p></sec><sec><title>Flow cytometry</title><p>Cell death was detected using the Muse<sup>&#x000ae;</sup> Annexin V Dead Cell kit (EMD Millipore). SKVO3/DDP cells were seeded in 6-well culture plates at a density of 2&#x000d7;10<sup>5</sup> cells/well. Following treatment under different experimental conditions, cells were trypsinized and resuspended in RPMI-1640 medium supplemented with 10% FBS at a concentration of 1x10<sup>6</sup> cells/ml. In the dark, cells were incubated with Annexin V at room temperature for 20 min. Finally, cells were measured using the Muse<sup>&#x000ae;</sup> Cell Analyzer (version 1.5.0.0; EMD Millipore). All experiments were performed in triplicate.</p></sec><sec><title>Mitochondrial membrane potential (&#x00394;&#x003a8;m)</title><p>Alterations in &#x00394;&#x003a8;m during the early stages of apoptosis were assessed using the Muse<sup>&#x000ae;</sup> MitoPotential assay (MCH 100110; EMD Millipore). SKOV3/DDP cells were treated with cisplatin alone or in combination with TAT-IDP<sup>S</sup>. Subsequently, cells were centrifuged at 3,000 &#x000d7; g for 5 min at room temperature, and the cell pellet was suspended in assay buffer (1&#x000d7;10<sup>5</sup> cells/100 <italic>&#x003bc;</italic>l). MitoPotential dye working solution was added, and the cell suspension was incubated at 37&#x000b0;C for 20 min. Following the addition of Muse<sup>&#x000ae;</sup> MitoPotential 7-aminoactinomycin D dye (propidium iodide) for 5 min, alterations in &#x00394;&#x003a8;m and in cellular plasma membrane permeabilization were assessed on the basis of the fluorescence intensities of both dyes, which were analyzed by flow cytometry (Muse<sup>&#x000ae;</sup> Cell Analyzer version 1.5.0.0; EMD Millipore).</p></sec><sec><title>Statistical analysis</title><p>Data are representative of three independent experiments performed in triplicate and are presented as the mean &#x000b1; standard deviation. Data analysis was performed using one-way analysis of variance, and Tukey's post-hoc test was used to determine statistical significance of all pairwise comparisons of interest. P&#x0003c;0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using the Complex Samples module in IBM SPSS Statistics 20.0 (SPSS, Inc., Chicago, IL, USA)</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>TAT-IDP<sup>S</sup> enhances cisplatin-induced cytosolic Ca<sup>2+</sup> elevation and mitochondrial Ca<sup>2+</sup> overload in SKOV3/DDP cells</title><p>TAT-IDP<sup>S</sup> can enhance IP3R-mediated Ca<sup>2+</sup> signals by disrupting the Bcl-2-IP3R interaction. The present study explored whether TAT-IDP<sup>S</sup> increased cisplatin-induced cytosolic and mitochondrial Ca<sup>2+</sup> levels in SKOV3/DDP cells. SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h and Ca<sup>2+</sup> levels were then examined in the mitochondria and cytoplasm. The Ca<sup>2+</sup>-sensitive fluorescent dyes Fluo-4/AM and Rhod-2/AM were used to detect cytosolic and mitochondrial Ca<sup>2+</sup> levels by confocal microscopy, respectively. Compared with in the control (untreated) group, cisplatin induced an elevation in free Ca<sup>2+</sup> in the cytosol and mitochondria. Furthermore, cisplatin-induced Ca<sup>2+</sup> elevation in the cytosol and mitochondria was further increased in the cells treated with cisplatin and TAT-IDP<sup>S</sup> (<xref rid="f1-ijmm-41-02-0809" ref-type="fig">Fig. 1</xref>).</p></sec><sec><title>TAT-IDP<sup>S</sup> increases cisplatin-induced apoptosis of SKOV3/DDP cells</title><p>To evaluate the effects of TAT-IDP<sup>S</sup> on cisplatin-induced growth inhibition and apoptosis, SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h and growth inhibition was examined using MTT assays. The results indicated that cisplatin induced growth inhibition in SKOV3/DDP cells. In addition, cotreatment with cisplatin and TAT-IDP<sup>S</sup> increased the growth inhibitory effects of cisplatin, whereas TAT-IDP<sup>S</sup> alone had no effect on cell viability compared with in the control group (<xref rid="f2-ijmm-41-02-0809" ref-type="fig">Fig. 2A</xref>). Under an optical microscope, it was demonstrated that SKOV3/DDP cells treated with cisplatin became round and fragmented compared with the control cells and that TAT-IDP<sup>S</sup> enhanced this effect (<xref rid="f2-ijmm-41-02-0809" ref-type="fig">Fig. 2B</xref>). Furthermore, flow cytometric analysis demonstrated that the rate of apoptosis in SKOV3/DDP cells treated with cisplatin and TAT-IDP<sup>S</sup> was higher than that in cells treated with cisplatin alone (<xref rid="f2-ijmm-41-02-0809" ref-type="fig">Fig. 2C and D</xref>). These results suggested that TAT-IDP<sup>S</sup> increased cisplatin-induced growth inhibition and apoptosis of SKOV3/DDP cells.</p></sec><sec><title>TAT-IDP<sup>S</sup> increases cisplatin-induced ER stress-associated apoptosis by increasing calpain-1 expression in SKOV3/DDP cells</title><p>Since calpain-1, which is a ubiquitous protease, can be activated by cytoplasmic Ca<sup>2+</sup> elevation (<xref rid="b16-ijmm-41-02-0809" ref-type="bibr">16</xref>), the present study detected the expression of calpain-1 using confocal microscopy. The results indicated that cotreatment with cisplatin and TAT-IDP<sup>S</sup> for 24 h increased cisplatin-induced calpain-1 accumulation (<xref rid="f3-ijmm-41-02-0809" ref-type="fig">Fig. 3A</xref>). Calpain-1 has been reported to enhance ER-associated apoptosis by cleaving its protein substrates (<xref rid="b16-ijmm-41-02-0809" ref-type="bibr">16</xref>). Subsequently, the present study investigated whether TAT-IDP<sup>S</sup> may sensitize SKOV3/DDP cells to cisplatin-induced ER stress-associated apoptosis. The expression levels of the following ER stress-associated apoptotic proteins: Calpain-1, PDI, CHOP and cleaved caspase-4, were detected by western blot analysis. Cisplatin induced the expression of all four proteins; furthermore, combined treatment with TAT-IDP<sup>S</sup> enhanced these effects (<xref rid="f3-ijmm-41-02-0809" ref-type="fig">Fig. 3B and C</xref>). These results suggested that TAT-IDP<sup>S</sup> may increase cisplatin-induced ER stress-associated apoptosis of SKOV3/DDP cells by increasing calpain-1 expression.</p></sec><sec><title>TAT-IDP<sup>S</sup> increases cisplatin-induced mitochondria-mediated apoptosis of SKOV3/DDP cells</title><p>Mitochondrial Ca<sup>2+</sup> overload can lead to opening of the mitochondrial inner membrane permeability transition pore (MPTP) and can subsequently induce aberrant dissipation of &#x00394;&#x003a8;m, thus resulting in cell apoptosis. Since an alteration in &#x00394;&#x003a8;m is considered an early event in apoptosis (<xref rid="b17-ijmm-41-02-0809" ref-type="bibr">17</xref>), the present study monitored the effects of TAT-IDP<sup>S</sup> and/or cisplatin on &#x00394;&#x003a8;m at 6 h. SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 6 h, and alterations in &#x00394;&#x003a8;m were determined using flow cytometry. TAT-IDP<sup>S</sup> enhanced the cisplatin-induced decrease in &#x00394;&#x003a8;m (<xref rid="f4-ijmm-41-02-0809" ref-type="fig">Fig. 4A and B</xref>). Finally, the expression levels of mitochondrial apoptosis-associated proteins (cytochrome <italic>c</italic>, Bcl-2, Bax and cleaved caspase-3) were detected using western blotting. The results indicated that cotreatment with cisplatin and TAT-IDP<sup>S</sup> for 24 h increased the cisplatin-induced Bax/Bcl-2 ratio, and the cisplatin-induced expression of cytochrome <italic>c</italic> and cleaved caspase-3 (<xref rid="f4-ijmm-41-02-0809" ref-type="fig">Fig. 4C and D</xref>). These results suggested that TAT-IDP<sup>S</sup> may further reduce the decrease in &#x00394;&#x003a8;m induced by cisplatin, which may subsequently contribute to mitochondria-mediated apoptosis of SKOV3/DDP cells.</p></sec><sec><title>2-APB reduces the growth inhibition and apoptosis induced by cotreatment with TAT-IDP<sup>S</sup> and cisplatin</title><p>To further confirm that mitochondrial Ca<sup>2+</sup> overload caused by cotreatment with TAT-IDP<sup>S</sup> and cisplatin derives from the ER, cells were treated with 2-APB, an IP3R antagonist (<xref rid="b18-ijmm-41-02-0809" ref-type="bibr">18</xref>). Cisplatin and TAT-IDP<sup>S</sup>-induced mitochondrial Ca<sup>2+</sup> elevation in SKOV3/DDP cells was markedly reduced in the presence of 2-APB (<xref rid="f5-ijmm-41-02-0809" ref-type="fig">Fig. 5A</xref>). In addition, 2-APB reduced the decrease in &#x00394;&#x003a8;m induced by cisplatin and TAT-IDP<sup>S</sup> (<xref rid="f5-ijmm-41-02-0809" ref-type="fig">Fig. 5B and C</xref>). Similarly, cisplatin and TAT-IDP<sup>S</sup>-induced growth inhibition and apoptosis of SKOV3/DDP cells was markedly reduced in the presence of 2-APB (<xref rid="f5-ijmm-41-02-0809" ref-type="fig">Fig. 5D&#x02013;F</xref>). Taken together, these results strongly indicated that mitochondrial Ca<sup>2+</sup> overload caused by cotreatment with TAT-IDP<sup>S</sup> and cisplatin was derived from the ER.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Bcl-2 is an anti-apoptotic protein that promotes cell survival predominantly by inhibiting the release of cytochrome <italic>c</italic> from the mitochondria via its BH3 domain. In addition, Bcl-2 inhibits cell apoptosis by reducing Ca<sup>2+</sup> release from the ER via its BH4 domain. Recently, targeting the BH3 and BH4 domains to generate Bcl-2 inhibitors for cancer therapy has attracted attention. Obatoclax is a BH3 mimetic that can induce apoptosis of numerous types of cancer cell by interacting with the Bcl-2 BH3 domain; this agent has been tested in a phase II clinical trial in patients (<xref rid="b19-ijmm-41-02-0809" ref-type="bibr">19</xref>). Furthermore, Deng <italic>et al</italic> reported that BDA-366, which is an antagonist of the Bcl-2 BH4 domain, can induce apoptosis of human myeloma U266 cells (<xref rid="b20-ijmm-41-02-0809" ref-type="bibr">20</xref>). The results of the present study demonstrated that by targeting BH4, TAT-IDP<sup>S</sup> increases cisplatin-induced apoptosis of SKOV3/DDP cells (<xref rid="f2-ijmm-41-02-0809" ref-type="fig">Fig. 2</xref>).</p><p>As a major intracellular Ca<sup>2+</sup> store, the ER serves a central role in intracellular Ca<sup>2+</sup> signal transduction, and controls cell death and survival. The release of large amounts of Ca<sup>2+</sup> from the ER promotes cell apoptosis by affecting cytoplasmic and mitochondrial Ca<sup>2+</sup> homeostasis. There is strong evidence to suggest that Bcl-2 directly inhibits proapoptotic Ca<sup>2+</sup> release from IP3R at the ER into the cytoplasm and mitochondria via its BH4 domain (<xref rid="b21-ijmm-41-02-0809" ref-type="bibr">21</xref>&#x02013;<xref rid="b23-ijmm-41-02-0809" ref-type="bibr">23</xref>). TAT-IDP<sup>S</sup> can reverse the Bcl-2-mediated inhibition of IP3-dependent Ca<sup>2+</sup> elevation by targeting the BH4 domain, subsequently triggering Ca<sup>2+</sup>-dependent apoptosis or increasing sensitivity toward proapoptotic stimuli (<xref rid="b15-ijmm-41-02-0809" ref-type="bibr">15</xref>). The present study clearly demonstrated that TAT-IDP<sup>S</sup> increased cisplatin-induced cytoplasmic and mitochondrial Ca<sup>2+</sup> elevation (<xref rid="f1-ijmm-41-02-0809" ref-type="fig">Fig. 1</xref>).</p><p>Elevation of cytoplasmic Ca<sup>2+</sup> levels can lead to activation of a series of Ca<sup>2+</sup>-sensitive enzymes. Calpain-1 is the target of cytoplasmic Ca<sup>2+</sup>, which was originally termed <italic>&#x003bc;</italic>-calpain based on the Ca<sup>2+</sup> concentration (<italic>&#x003bc;</italic>M range) required for its optimal activity (<xref rid="b24-ijmm-41-02-0809" ref-type="bibr">24</xref>). Calpain-1 also participates in the apoptotic pathway triggered by ER stress. Matsuzaki <italic>et al</italic> confirmed that Ca<sup>2+</sup>-dependent calpain activation promoted neural cell death by inducing the processing and activation of caspase-4 (<xref rid="b25-ijmm-41-02-0809" ref-type="bibr">25</xref>). According to the results of confocal microscopy and western blot analyses, the present study revealed that TAT-IDP<sup>S</sup> increased cisplatin-induced calpain-1 expression (<xref rid="f3-ijmm-41-02-0809" ref-type="fig">Fig. 3</xref>) and increased cisplatin-induced ER stress-associated apoptosis of SKOV3/DDP cells.</p><p>Mitochondria are exposed to high Ca<sup>2+</sup> concentrations following the release of Ca<sup>2+</sup> from the ER. Accumulation of Ca<sup>2+</sup> in the mitochondrial matrix can lead to opening of the MPTP, which in turn causes mitochondrial swelling and rupture, accompanied by dissipation of &#x00394;&#x003a8;m (<xref rid="b26-ijmm-41-02-0809" ref-type="bibr">26</xref>&#x02013;<xref rid="b28-ijmm-41-02-0809" ref-type="bibr">28</xref>). The &#x00394;&#x003a8;m collapse further induces rupture of the outer membrane and subsequent release of mitochondrial apoptotic factors, including cytochrome <italic>c</italic>, into the cytosol, finally leading to cell apoptosis (<xref rid="b29-ijmm-41-02-0809" ref-type="bibr">29</xref>,<xref rid="b30-ijmm-41-02-0809" ref-type="bibr">30</xref>). Our previous study demonstrated that mitochondrial Ca<sup>2+</sup> levels are closely associated with cisplatin resistance in ovarian carcinoma cells (<xref rid="b11-ijmm-41-02-0809" ref-type="bibr">11</xref>). The present study demonstrated that TAT-IDP<sup>S</sup> increased cisplatin-induced &#x00394;&#x003a8;m collapse and mitochondrial-mediated apoptosis of SKOV3/DDP cells. Using 2-APB to effectively block ER Ca<sup>2+</sup> release, the present study further confirmed that TAT-IDP<sup>S</sup> and cisplatin-induced mitochondrial Ca<sup>2+</sup> overload is derived from the ER (<xref rid="f5-ijmm-41-02-0809" ref-type="fig">Fig. 5A</xref>).</p><p>In conclusion, the results of the present study indicated that TAT-IDP<sup>S</sup> increased the cisplatin-induced elevation of cytoplasmic and mitochondrial Ca<sup>2+</sup>, which further increased cisplatin-induced ER stress-mediated apoptosis by increasing calpain-1 expression and activating the mitochondrial apoptotic pathway. These results suggested that Ca<sup>2+</sup> release from the ER may regulate cisplatin-induced SKOV3/DDP cell apoptosis, providing a rationale for drugs that specifically disrupt the Bcl-2-IP3R interaction as a novel tool for the treatment of ovarian cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>The present study was supported by the National Nature and Science Foundation of China (NSFC grant nos. 81372793, 81472419 and 81202552) and the Department of Education of Jilin Province Project (grant no. 2016237). We thank Liwen Bianji for editing the English in this manuscript.</p></ack><ref-list><title>References</title><ref id="b1-ijmm-41-02-0809"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name></person-group><article-title>Kr&#x000fc;ppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells</article-title><source>Cancer Sci</source><volume>107</volume><fpage>242</fpage><lpage>249</lpage><year>2016</year><pub-id pub-id-type="doi">10.1111/cas.12864</pub-id><!--<pub-id pub-id-type="pmcid">4814257</pub-id>--><pub-id pub-id-type="pmid">26676883</pub-id></element-citation></ref><ref id="b2-ijmm-41-02-0809"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XX</given-names></name><name><surname>Xie</surname><given-names>FF</given-names></name><name><surname>Zhu</surname><given-names>XJ</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>SS</given-names></name><name><surname>Gong</surname><given-names>LH</given-names></name><name><surname>Qiu</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Jiang</surname><given-names>QW</given-names></name><name><surname>Mei</surname><given-names>XL</given-names></name><etal/></person-group><article-title>Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>14926</fpage><lpage>14939</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.3717</pub-id><!--<pub-id pub-id-type="pmcid">4558126</pub-id>--><pub-id pub-id-type="pmid">25962959</pub-id></element-citation></ref><ref id="b3-ijmm-41-02-0809"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>WA</given-names></name><name><surname>Ahad</surname><given-names>A</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name></person-group><article-title>The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update</article-title><source>Arch Toxicol</source><volume>89</volume><fpage>289</fpage><lpage>317</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s00204-014-1448-7</pub-id><pub-id pub-id-type="pmid">25618543</pub-id></element-citation></ref><ref id="b4-ijmm-41-02-0809"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>RJ</given-names></name></person-group><article-title>Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins</article-title><source>Biochem Soc Trans</source><volume>28</volume><fpage>51</fpage><lpage>56</lpage><year>2000</year><pub-id pub-id-type="doi">10.1042/bst0280051</pub-id><pub-id pub-id-type="pmid">10816098</pub-id></element-citation></ref><ref id="b5-ijmm-41-02-0809"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>N</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics</article-title><source>Exp Cell Res</source><volume>335</volume><fpage>68</fpage><lpage>81</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.04.016</pub-id><pub-id pub-id-type="pmid">25936772</pub-id></element-citation></ref><ref id="b6-ijmm-41-02-0809"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>N</given-names></name><name><surname>Zha</surname><given-names>J</given-names></name><name><surname>Peale</surname><given-names>FV</given-names></name><name><surname>Yue</surname><given-names>P</given-names></name><name><surname>Fairbrother</surname><given-names>WJ</given-names></name><name><surname>Belmont</surname><given-names>LD</given-names></name></person-group><article-title>Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models</article-title><source>Mol Cancer Ther</source><volume>11</volume><fpage>1026</fpage><lpage>1035</lpage><year>2012</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0693</pub-id><pub-id pub-id-type="pmid">22302098</pub-id></element-citation></ref><ref id="b7-ijmm-41-02-0809"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Owonikoko</surname><given-names>TK</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Sica</surname><given-names>GL</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Magis</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Small-molecule Bcl2 BH4 antagonist for lung cancer therapy</article-title><source>Cancer Cell</source><volume>27</volume><fpage>852</fpage><lpage>863</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ccell.2015.04.010</pub-id><!--<pub-id pub-id-type="pmcid">4470473</pub-id>--><pub-id pub-id-type="pmid">26004684</pub-id></element-citation></ref><ref id="b8-ijmm-41-02-0809"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name><name><surname>Inagaki</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Niiya</surname><given-names>A</given-names></name><name><surname>Usui</surname><given-names>Y</given-names></name><name><surname>Oguchi</surname><given-names>K</given-names></name></person-group><article-title>Neuroprotective effects of propofol on ER stress-mediated apoptosis in neuroblastoma SH-SY5Y cells</article-title><source>Eur J Pharmacol</source><volume>725</volume><fpage>47</fpage><lpage>54</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.01.003</pub-id><pub-id pub-id-type="pmid">24444437</pub-id></element-citation></ref><ref id="b9-ijmm-41-02-0809"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>J</given-names></name><name><surname>Agellon</surname><given-names>LB</given-names></name><name><surname>Michalak</surname><given-names>M</given-names></name></person-group><article-title>Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling</article-title><source>Biochem Biophys Res Commun</source><volume>460</volume><fpage>114</fpage><lpage>121</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.004</pub-id><pub-id pub-id-type="pmid">25998740</pub-id></element-citation></ref><ref id="b10-ijmm-41-02-0809"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>JT</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>XY</given-names></name><name><surname>Yi</surname><given-names>HW</given-names></name><name><surname>Zhang</surname><given-names>ZC</given-names></name><name><surname>Sun</surname><given-names>LK</given-names></name></person-group><article-title>The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy</article-title><source>Oncol Rep</source><volume>30</volume><fpage>2677</fpage><lpage>2684</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/or.2013.2771</pub-id><pub-id pub-id-type="pmid">24100381</pub-id></element-citation></ref><ref id="b11-ijmm-41-02-0809"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis</article-title><source>Oncol Rep</source><volume>34</volume><fpage>3051</fpage><lpage>3060</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/or.2015.4283</pub-id><pub-id pub-id-type="pmid">26398138</pub-id></element-citation></ref><ref id="b12-ijmm-41-02-0809"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonder</surname><given-names>DE</given-names></name><name><surname>McCarthy</surname><given-names>KD</given-names></name></person-group><article-title>Astrocytic Gq-GPCR-linked IP3R-dependent Ca<sup>2+</sup> signaling does not mediate neurovascular coupling in mouse visual cortex in vivo</article-title><source>J Neurosci</source><volume>34</volume><fpage>13139</fpage><lpage>13150</lpage><year>2014</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2591-14.2014</pub-id><!--<pub-id pub-id-type="pmcid">4172806</pub-id>--><pub-id pub-id-type="pmid">25253859</pub-id></element-citation></ref><ref id="b13-ijmm-41-02-0809"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wild</surname><given-names>C</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wold</surname><given-names>EA</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name></person-group><article-title>BH4 domain of Bcl-2 as a novel target for cancer therapy</article-title><source>Drug Discov Today</source><volume>21</volume><fpage>989</fpage><lpage>996</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.drudis.2015.11.008</pub-id><!--<pub-id pub-id-type="pmcid">4882289</pub-id>--><pub-id pub-id-type="pmid">26631752</pub-id></element-citation></ref><ref id="b14-ijmm-41-02-0809"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>Monaco</surname><given-names>G</given-names></name><name><surname>La Rovere</surname><given-names>R</given-names></name><name><surname>Welkenhuyzen</surname><given-names>K</given-names></name><name><surname>Kiviluoto</surname><given-names>S</given-names></name><name><surname>Vervliet</surname><given-names>T</given-names></name><name><surname>Molg&#x000f3;</surname><given-names>J</given-names></name><name><surname>Distelhorst</surname><given-names>CW</given-names></name><name><surname>Missiaen</surname><given-names>L</given-names></name><name><surname>Mikoshiba</surname><given-names>K</given-names></name><etal/></person-group><article-title>IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2</article-title><source>Cell Death Dis</source><volume>4</volume><fpage>e632</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cddis.2013.140</pub-id><!--<pub-id pub-id-type="pmcid">3674349</pub-id>--><pub-id pub-id-type="pmid">23681227</pub-id></element-citation></ref><ref id="b15-ijmm-41-02-0809"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Harr</surname><given-names>MW</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name><name><surname>Monaco</surname><given-names>G</given-names></name><name><surname>Parys</surname><given-names>JB</given-names></name><name><surname>De Smedt</surname><given-names>H</given-names></name><name><surname>Rong</surname><given-names>YP</given-names></name><name><surname>Molitoris</surname><given-names>JK</given-names></name><name><surname>Lam</surname><given-names>M</given-names></name><name><surname>Ryder</surname><given-names>C</given-names></name><etal/></person-group><article-title>Induction of Ca<sup>2+</sup>-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction</article-title><source>Blood</source><volume>117</volume><fpage>2924</fpage><lpage>2934</lpage><year>2011</year><pub-id pub-id-type="doi">10.1182/blood-2010-09-307405</pub-id><!--<pub-id pub-id-type="pmcid">3062302</pub-id>--><pub-id pub-id-type="pmid">21193695</pub-id></element-citation></ref><ref id="b16-ijmm-41-02-0809"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudry</surname><given-names>M</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name></person-group><article-title>Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration</article-title><source>Trends Neurosci</source><volume>39</volume><fpage>235</fpage><lpage>245</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.tins.2016.01.007</pub-id><!--<pub-id pub-id-type="pmcid">4818674</pub-id>--><pub-id pub-id-type="pmid">26874794</pub-id></element-citation></ref><ref id="b17-ijmm-41-02-0809"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Dan</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><article-title>Real-time detection of intracellular reactive oxygen species and mitochondrial membrane potential in THP-1 macrophages during ultrasonic irradiation for optimal sonodynamic therapy</article-title><source>Ultrason Sonochem</source><volume>22</volume><fpage>7</fpage><lpage>14</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ultsonch.2014.06.016</pub-id><pub-id pub-id-type="pmid">25023826</pub-id></element-citation></ref><ref id="b18-ijmm-41-02-0809"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peppiatt</surname><given-names>CM</given-names></name><name><surname>Collins</surname><given-names>TJ</given-names></name><name><surname>Mackenzie</surname><given-names>L</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Holmes</surname><given-names>AB</given-names></name><name><surname>Bootman</surname><given-names>MD</given-names></name><name><surname>Berridge</surname><given-names>MJ</given-names></name><name><surname>Seo</surname><given-names>JT</given-names></name><name><surname>Roderick</surname><given-names>HL</given-names></name></person-group><article-title>2-Aminoethoxydiphenyl borate (2-APB) antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps and has a use-dependent and slowly reversible action on store-operated calcium entry channels</article-title><source>Cell Calcium</source><volume>34</volume><fpage>97</fpage><lpage>108</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S0143-4160(03)00026-5</pub-id><pub-id pub-id-type="pmid">12767897</pub-id></element-citation></ref><ref id="b19-ijmm-41-02-0809"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz-Roberts</surname><given-names>JL</given-names></name><name><surname>Shajahan</surname><given-names>AN</given-names></name><name><surname>Cook</surname><given-names>KL</given-names></name><name><surname>Warri</surname><given-names>A</given-names></name><name><surname>Abu-Asab</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name></person-group><article-title>GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autopha-gosomal lysis in antiestrogen-resistant breast cancer cells</article-title><source>Mol Cancer Ther</source><volume>12</volume><fpage>448</fpage><lpage>459</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0617</pub-id><!--<pub-id pub-id-type="pmcid">3624027</pub-id>--><pub-id pub-id-type="pmid">23395885</pub-id></element-citation></ref><ref id="b20-ijmm-41-02-0809"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Nooka</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Matulis</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>J</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Boise</surname><given-names>LH</given-names></name><name><surname>Galipeau</surname><given-names>J</given-names></name><etal/></person-group><article-title>BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth</article-title><source>Oncotarget</source><volume>7</volume><fpage>27753</fpage><lpage>27763</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.8513</pub-id><!--<pub-id pub-id-type="pmcid">5053685</pub-id>--><pub-id pub-id-type="pmid">27049723</pub-id></element-citation></ref><ref id="b21-ijmm-41-02-0809"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>La Rovere</surname><given-names>RM</given-names></name><name><surname>Janssens</surname><given-names>A</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name><name><surname>Parys</surname><given-names>JB</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name></person-group><article-title>HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP3 receptor/Bcl-2 complexes</article-title><source>Int J Dev Biol</source><volume>59</volume><fpage>391</fpage><lpage>398</lpage><year>2015</year><pub-id pub-id-type="doi">10.1387/ijdb.150213gb</pub-id><pub-id pub-id-type="pmid">26260683</pub-id></element-citation></ref><ref id="b22-ijmm-41-02-0809"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parys</surname><given-names>JB</given-names></name></person-group><article-title>The IP3 receptor as a hub for Bcl-2 family proteins in cell death control and beyond</article-title><source>Sci Signal</source><volume>7</volume><fpage>pe4</fpage><year>2014</year><pub-id pub-id-type="doi">10.1126/scisignal.2005093</pub-id><pub-id pub-id-type="pmid">24518292</pub-id></element-citation></ref><ref id="b23-ijmm-41-02-0809"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>Vervloessem</surname><given-names>T</given-names></name><name><surname>Kiviluoto</surname><given-names>S</given-names></name><name><surname>Bittremieux</surname><given-names>M</given-names></name><name><surname>Parys</surname><given-names>JB</given-names></name><name><surname>De Smedt</surname><given-names>H</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name></person-group><article-title>A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum</article-title><source>Biochim Biophys Acta</source><volume>1843</volume><fpage>2240</fpage><lpage>2252</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.04.017</pub-id><pub-id pub-id-type="pmid">24768714</pub-id></element-citation></ref><ref id="b24-ijmm-41-02-0809"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>X</given-names></name><name><surname>Storr</surname><given-names>SJ</given-names></name><name><surname>Ahmad</surname><given-names>NS</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Moseley</surname><given-names>PM</given-names></name><name><surname>Televantou</surname><given-names>D</given-names></name><name><surname>Cresti</surname><given-names>N</given-names></name><name><surname>Boddy</surname><given-names>A</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name><name><surname>Martin</surname><given-names>SG</given-names></name></person-group><article-title>Calpain-1 is associated with adverse relapse free survival in breast cancer: A confirmatory study</article-title><source>Histopathology</source><volume>68</volume><fpage>1021</fpage><lpage>1029</lpage><year>2016</year><pub-id pub-id-type="doi">10.1111/his.12896</pub-id><pub-id pub-id-type="pmid">26496999</pub-id></element-citation></ref><ref id="b25-ijmm-41-02-0809"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>S</given-names></name><name><surname>Hiratsuka</surname><given-names>T</given-names></name><name><surname>Kuwahara</surname><given-names>R</given-names></name><name><surname>Katayama</surname><given-names>T</given-names></name><name><surname>Tohyama</surname><given-names>M</given-names></name></person-group><article-title>Caspase-4 is partially cleaved by calpain via the impairment of Ca<sup>2+</sup> homeostasis under the ER stress</article-title><source>Neurochem Int</source><volume>56</volume><fpage>352</fpage><lpage>356</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.neuint.2009.11.007</pub-id><pub-id pub-id-type="pmid">19931333</pub-id></element-citation></ref><ref id="b26-ijmm-41-02-0809"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>GA</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name></person-group><article-title>Regulation of mitochondrial metabolism by ER Ca<sup>2+</sup> release: An intimate connection</article-title><source>Trends Biochem Sci</source><volume>25</volume><fpage>215</fpage><lpage>221</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0968-0004(00)01585-1</pub-id><pub-id pub-id-type="pmid">10782088</pub-id></element-citation></ref><ref id="b27-ijmm-41-02-0809"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Stockum</surname><given-names>S</given-names></name><name><surname>Giorgio</surname><given-names>V</given-names></name><name><surname>Trevisan</surname><given-names>E</given-names></name><name><surname>Lippe</surname><given-names>G</given-names></name><name><surname>Glick</surname><given-names>GD</given-names></name><name><surname>Forte</surname><given-names>MA</given-names></name><name><surname>Da-R&#x000e8;</surname><given-names>C</given-names></name><name><surname>Checchetto</surname><given-names>V</given-names></name><name><surname>Mazzotta</surname><given-names>G</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><etal/></person-group><article-title>F-ATPase of Drosophila melanogaster forms 53-picosiemen (53-pS) channels responsible for mitochondrial Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release</article-title><source>J Biol Chem</source><volume>290</volume><fpage>4537</fpage><lpage>4544</lpage><year>2015</year><pub-id pub-id-type="doi">10.1074/jbc.C114.629766</pub-id><!--<pub-id pub-id-type="pmcid">4335195</pub-id>--><pub-id pub-id-type="pmid">25550160</pub-id></element-citation></ref><ref id="b28-ijmm-41-02-0809"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000fc;l&#x000f6;p</surname><given-names>L</given-names></name><name><surname>Rajki</surname><given-names>A</given-names></name><name><surname>Maka</surname><given-names>E</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>MJ</given-names></name><name><surname>Sp&#x000e4;t</surname><given-names>A</given-names></name></person-group><article-title>Mitochondrial Ca<sup>2+</sup> uptake correlates with the severity of the symptoms in autosomal dominant optic atrophy</article-title><source>Cell Calcium</source><volume>57</volume><fpage>49</fpage><lpage>55</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.ceca.2014.11.008</pub-id><pub-id pub-id-type="pmid">25533789</pub-id></element-citation></ref><ref id="b29-ijmm-41-02-0809"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajn&#x000f3;czky</surname><given-names>G</given-names></name><name><surname>Csord&#x000e1;s</surname><given-names>G</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Garcia-Perez</surname><given-names>C</given-names></name><name><surname>Saotome</surname><given-names>M</given-names></name><name><surname>Sinha Roy</surname><given-names>S</given-names></name><name><surname>Yi</surname><given-names>M</given-names></name></person-group><article-title>Mitochondrial calcium signalling and cell death: Approaches for assessing the role of mitochondrial Ca<sup>2+</sup> uptake in apoptosis</article-title><source>Cell Calcium</source><volume>40</volume><fpage>553</fpage><lpage>560</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.ceca.2006.08.016</pub-id><pub-id pub-id-type="pmid">17074387</pub-id></element-citation></ref><ref id="b30-ijmm-41-02-0809"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgi</surname><given-names>C</given-names></name><name><surname>Baldassari</surname><given-names>F</given-names></name><name><surname>Bononi</surname><given-names>A</given-names></name><name><surname>Bonora</surname><given-names>M</given-names></name><name><surname>De Marchi</surname><given-names>E</given-names></name><name><surname>Marchi</surname><given-names>S</given-names></name><name><surname>Missiroli</surname><given-names>S</given-names></name><name><surname>Patergnani</surname><given-names>S</given-names></name><name><surname>Rimessi</surname><given-names>A</given-names></name><name><surname>Suski</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Mitochondrial Ca(2+) and apoptosis</article-title><source>Cell Calcium</source><volume>52</volume><fpage>36</fpage><lpage>43</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ceca.2012.02.008</pub-id><!--<pub-id pub-id-type="pmcid">3396846</pub-id>--><pub-id pub-id-type="pmid">22480931</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ijmm-41-02-0809" orientation="portrait" position="float"><label>Figure 1</label><caption><p>TAT-IDP<sup>S</sup> increases cisplatin-induced cytosolic Ca<sup>2+</sup> elevation and mitochondrial Ca<sup>2+</sup> overload in SKOV3/DDP cells. SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h and were then incubated with the fluorescent calcium indicators Fluo-4/AM and Rhod-2/AM. Cytosolic and mitochondrial Ca<sup>2+</sup> levels were observed by confocal microscopy (scale bar, 5 <italic>&#x003bc;</italic>m). TAT-IDP<sup>S</sup>, TAT-fused IP3R-derived peptide.</p></caption><graphic xlink:href="IJMM-41-02-0809-g00"/></fig><fig id="f2-ijmm-41-02-0809" orientation="portrait" position="float"><label>Figure 2</label><caption><p>TAT-IDP<sup>S</sup> increases cisplatin-induced apoptosis of SKOV3/DDP cells. (A) SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h, and cell viability was determined using MTT assays. Data are presented as the mean &#x000b1; standard deviation. (B) Optical microscopy images of SKOV3/DDP cells treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h (scale bar, 50 <italic>&#x003bc;</italic>m). (C) SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h, and were stained with Annexin V. (D) Quantification of apoptosis of SKOV3/DDP cells exposed to cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h. Data are presented as the mean &#x000b1; standard deviation, n=3. <sup>*</sup>P&#x0003c;0.05 vs. the control group; <sup>#</sup>P&#x0003c;0.05 vs. the cisplatin group. TAT-IDP<sup>S</sup>, TAT-fused IP3R-derived peptide.</p></caption><graphic xlink:href="IJMM-41-02-0809-g01"/></fig><fig id="f3-ijmm-41-02-0809" orientation="portrait" position="float"><label>Figure 3</label><caption><p>TAT-IDP<sup>S</sup> increases cisplatin-induced endoplasmic reticulum stress-associated apoptosis by increasing calpain-1 expression in SKOV3/DDP cells. (A) Detection of calpain-1 in the cytoplasm of SKOV3/DDP cells exposed to cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h, under a confocal microscope (scale bar, 10 <italic>&#x003bc;</italic>m). (B) Western blot analysis was performed to detect the expression levels of calpain-1, PDI, CHOP and cleaved caspase-4 in SKOV3/DDP cells following treatment with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDPS (25 <italic>&#x003bc;</italic>M) for 24 h. (C) Semi-quantification of calpain-1, PDI, CHOP and cleaved caspase-4 expression. Data are presented as the mean &#x000b1; standard deviation, n=3. <sup>*</sup>P&#x0003c;0.05 vs. the control group; <sup>#</sup>P&#x0003c;0.05 vs. the cisplatin group. CHOP, CCAAT-enhancer-binding protein homologous protein; PDI, protein disulfide isomerase; TAT-IDP<sup>S</sup>, TAT-fused IP3R-derived peptide.</p></caption><graphic xlink:href="IJMM-41-02-0809-g02"/></fig><fig id="f4-ijmm-41-02-0809" orientation="portrait" position="float"><label>Figure 4</label><caption><p>TAT-IDP<sup>S</sup> increases cisplatin-induced mitochondria-mediated apoptosis of SKOV3/DDP cells. (A) SKOV3/DDP cells were treated with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 6 h. &#x00394;&#x003a8;m was assessed by staining with MitoPotential dye and 7-aminoactinomycin D, and was analyzed using the Muse<sup>&#x000ae;</sup> Cell Analyzer. (B) Quantification of &#x00394;&#x003a8;m. Data are presented as the mean &#x000b1; standard deviation, n=3. (C) Western blot analysis of the expression of cytochrome <italic>c</italic>, Bcl-2, Bax and cleaved caspase-3 in SKOV3/DDP cells following treatment with cisplatin (15 <italic>&#x003bc;</italic>g/ml) and/or TAT-IDP<sup>S</sup> (25 <italic>&#x003bc;</italic>M) for 24 h. (D) Semi-quantification of cytochrome <italic>c</italic>, Bcl-2, Bax, and cleaved caspase-3 expression. Data are presented as the mean &#x000b1; standard deviation, n=3. <sup>*</sup>P&#x0003c;0.05 vs. the control group; <sup>#</sup>P&#x0003c;0.05 vs. the cisplatin group. &#x00394;&#x003a8;m, mitochondrial membrane potential; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; TAT-IDP<sup>S</sup>, TAT-fused IP3R-derived peptide.</p></caption><graphic xlink:href="IJMM-41-02-0809-g03"/></fig><fig id="f5-ijmm-41-02-0809" orientation="portrait" position="float"><label>Figure 5</label><caption><p>2-APB reduces the growth inhibition and apoptosis induced by TAT-IDP<sup>S</sup> and cisplatin. SKOV3/DDP cells were treated with 15 <italic>&#x003bc;</italic>g/ml cisplatin and 25 <italic>&#x003bc;</italic>M TAT-IDP<sup>S</sup> in the presence or absence of 50 <italic>&#x003bc;</italic>M 2-APB for 24 h. (A) Cells were incubated with the fluorescent calcium indicator Rhod-2/AM and mitochondrial Ca<sup>2+</sup> levels were observed by confocal microscopy (scale bar, 40 <italic>&#x003bc;</italic>m). (B) &#x00394;&#x003a8;m was assessed by staining with MitoPotential dye and 7-aminoactinomycin D, and was analyzed using the Muse<sup>&#x000ae;</sup> Cell Analyzer. (C) Quantification of &#x00394;&#x003a8;m. Data are presented as the mean &#x000b1; standard deviation, n=3. (D) Cell viability was determined using an MTT assay. Data are presented as the mean &#x000b1; standard deviation. (E) Western blot analysis of the expression of cytochrome <italic>c</italic> and cleaved caspase-3 in SKOV3/DDP cells. (F) Semi-quantification of cytochrome <italic>c</italic> and cleaved caspase-3 expression. Data are presented as the mean &#x000b1; standard deviation, n=3. <sup>*</sup>P&#x0003c;0.05 vs. the control group; <sup>#</sup>P&#x0003c;0.05 vs. the cisplatin + TAT-IDP<sup>S</sup> group. &#x00394;&#x003a8;m, mitochondrial membrane potential; 2-APB, 2-aminoethyl diphenylborinate; TAT-IDP<sup>S</sup>, TAT-fused IP3R-derived peptide.</p></caption><graphic xlink:href="IJMM-41-02-0809-g04"/></fig></floats-group></article>